Radiological responses
Tumors, tumors, lung disease, liver disease
TUMORS, TUMORS, LUNG DISEASE, LIVER DISEASE
By independent review in 37/66 patients (56.1%) with evaluable scans, the objective response rate by RECIST 1.1 was 6/19 (32%) for combination therapy and 3/18 (17%) for monotherapy, with complete responses in 1/19 (5%) and 2/18 (11%) patients, respectively (one with Child–Pugh class B) (Table RECIST v1.1 responses among evaluable patients.Abbreviations: AutEMdev, generator of electromagnetics, EMF, electromagnetic field; RECIST, Response Evaluation Criteria in Solid Tumors.Not all of the 66 patients in the study population had follow‐up scans available. 10 patients with data were not evaluable by independent review.One of these four patients had a complete resection after EMF monotherapy with the AutEMdev and remained cancer‐free.Excluding patient who received a complete resection and remained cancer‐free.Imaging of two patients with partial radiographic responses. (A) Metastatic liver disease in a patient receiving 35 AutEMdev EMF exposure procedures as monotherapy (magnetic resonance imaging). (B) Metastatic lung disease in a patient receiving 31 AutEMdev EMF exposure procedures in combination with first‐line lenvatinib (computed tomography). Red arrows indicate tumors. Abbreviations: AutEMdev indicates Autem electromagnetic device; EMF, electromagnetic field.